Yahoo Αναζήτηση Διαδυκτίου

Αποτελέσματα Αναζήτησης

1. www.destinyclinicaltrials.com › en › trial-locatorFind a DESTINY Metastatic Breast Cancer Clinical Trial

   www.destinyclinicaltrials.com › en › trial-locator

   • Αποθηκευμένο αντίγραφο

   Use our locator tool to find DESTINY clinical trial locations and contact information; for eligible patients with metastatic breast cancer.

2. www.destinyclinicaltrials.com › enDESTINY Clinical Trials for Metastatic Breast Cancer

   www.destinyclinicaltrials.com › en

   • Αποθηκευμένο αντίγραφο

   Find information on Phase 3 fam- trastuzumab deruxtecan (DS-8201) trials; for eligible patients with metastatic breast cancer.

3. ucla.clinicaltrials.researcherprofiles.org › breast-cancerUCLA Breast Cancer Clinical Trials for 2024 — Los Angeles

   ucla.clinicaltrials.researcherprofiles.org › breast-cancer

   • Αποθηκευμένο αντίγραφο

   14 Νοε 2024 · Breast Cancer clinical trials at UCLA . 83 in progress, 32 open to eligible people

4. www.cancer.gov › research › participateBreast Cancer Clinical Trials - NCI - National Cancer Institute

   www.cancer.gov › research › participate

   • Αποθηκευμένο αντίγραφο

   NCI supports clinical trials studying new and more effective ways to detect and treat cancer. Find clinical trials for breast cancer.

5. www.breastcancertrials.org › bct_nation › browse_trialsBrowse Trials - BreastCancerTrials.org

   www.breastcancertrials.org › bct_nation › browse_trials

   • Αποθηκευμένο αντίγραφο

   27 Νοε 2024 · breast cancer recurrence, living with metastatic disease, as well as breast cancer survivors who have completed treatment. Use the search box and filters to find a trial that’s right for you.

6. clinicaloptions.com › activities › oncologyDESTINY-Breast06: Phase III Trial of Trastuzumab Deruxtecan vs...

   clinicaloptions.com › activities › oncology

   • Αποθηκευμένο αντίγραφο

   5 Ιουν 2024 · Results from the phase III DESTINY-Breast06 trial demonstrated clinically meaningful progression-free survival benefit with T-DXd vs single-agent chemotherapy for patients with HR+/HER2-low or HER2-ultralow metastatic breast cancer after progression on endocrine-based therapy with or without targeted therapy.

7. www.daiichisankyo.com › media › press_releaseDESTINY-Breast05 Head-to-Head Phase 3 Trial of ENHERTU

   www.daiichisankyo.com › media › press_release

   • Αποθηκευμένο αντίγραφο

   4 Νοε 2020 · DESTINY-Breast05 is a phase 3, multicenter, randomized, open-label, active-controlled study of ENHERTU versus T-DM1 in patients with high-risk HER2 positive primary breast cancer who have residual invasive disease in breast or axillary lymph nodes following neo-adjuvant therapy.